logo
Twitter
Discord
Email
logo
Alkermes plc

Alkermes plc

NASDAQ•ALKS
CEO: Mr. Richard F. Pops
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1991-07-16
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Contact Information
Connaught House, 1 Burlington Road Dublin 4, Dublin, D04 C5Y6, Ireland
353-1-772-8000
www.alkermes.com
Market Cap
$4.80B
P/E (TTM)
14.1
45.9
Dividend Yield
--
52W High
$36.45
52W Low
$25.17
52W Range
34%
3.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$394.19M+4.24%
4-Quarter Trend

EPS

$0.50-12.28%
4-Quarter Trend

FCF

$84.36M+15.04%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Product Sales Show Strength Net product sales reached $869.2 M for nine months, increasing $93.3 M (12.0%) driven by LYBALVI and ARISTADA growth.
Operating Cash Flow Rises Cash provided by operating activities totaled $350.7 M for nine months, a $101.9 M increase compared to the prior year period.
R&D Investment Accelerates Total R&D expenses grew to $230.9 M for nine months, reflecting increased spend on development programs like Alixorexton.
Strong Cash Position Maintained Total cash and equivalents ended at $616.4 M as of September 30, 2025, significantly higher than $291.1 M at year-end 2024.

Risk Factors

INVEGA Royalty Revenue Decline Royalty revenues dropped $121.6 M for nine months due to the August 2024 expiration of the INVEGA SUSTENNA royalty in the U.S.
Net Income Under Pressure Net income from continuing operations decreased $34.1 M for nine months, despite strong underlying product sales performance.
Avadel Acquisition Integration Risk Failure to successfully integrate Avadel business or realize anticipated synergies post-closing could adversely affect financial condition.
Ongoing Patent Litigation Exposure Multiple patent infringement lawsuits concerning LYBALVI and VIVITROL create uncertainty regarding future IP protection.

Outlook

Avadel Acquisition Expected Closing Proposed Acquisition of Avadel is currently expected to be completed in the first quarter of 2026, subject to customary conditions.
Alixorexton Advances to Phase 3 Proceeding with Phase 3 program initiation for Alixorexton in narcolepsy following positive safety and efficacy results from Vibrance-1.
Financing Bridge Facility Planned Company plans to obtain permanent financing to replace the approximately $1.2 B Bridge Credit Facility arranged for the acquisition.
Q4 Acquisition Cost Incurrence Anticipate incurring approximately $15.0 M to $20.0 M in costs during the fourth quarter of 2025 related to the Proposed Acquisition.

Peer Comparison

Revenue (TTM)

PTC Therapeutics, Inc.PTCT
$1.78B
+97.5%
Alkermes plcALKS
$1.52B
+1.1%
ACADIA Pharmaceuticals Inc.ACAD
$1.05B
+12.7%

Gross Margin (Latest Quarter)

PTC Therapeutics, Inc.PTCT
92.5%
-2.0 pp
ACADIA Pharmaceuticals Inc.ACAD
92.2%
-0.3 pp
Alkermes plcALKS
86.9%
+3.6 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
NUVL$7.02B-18.3-39.5%0.0%
PCVX$6.37B-10.1-21.1%2.7%
PTCT$6.05B7.9-182.7%15.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.9%
Flat Growth
4Q Net Income CAGR
-17.3%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 28, 2025|
    Revenue: $394.19M+4.2%
    |
    EPS: $0.50-12.3%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 29, 2025|
    Revenue: $390.66M-2.1%
    |
    EPS: $0.53-1.9%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 1, 2025|
    Revenue: $306.51M-12.5%
    |
    EPS: $0.14-36.4%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 12, 2025|
    Revenue: $1.56B-6.4%
    |
    EPS: $2.22+3.7%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 24, 2024|
    Revenue: $378.14M-0.7%
    |
    EPS: $0.57+96.6%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 24, 2024|
    Revenue: $399.13M-35.4%
    |
    EPS: $0.54-62.2%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 1, 2024|
    Revenue: $350.37M+21.8%
    |
    EPS: $0.22-188.0%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $1.66B+49.6%
    |
    EPS: $2.14+320.6%
    Beat